Home › Research › TREM2 and immune genetics
The innate immune system in Alzheimer's disease
Boutajangout A, Wisniewski T.. International journal of cell biology, 2013-10-02
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is the leading cause for dementia in the world. It is characterized by two biochemically distinct types of protein aggregates: amyloid β (A β ) peptide in the forms of parenchymal amyloid plaques and congophilic amyloid angiopathy (CAA) and aggregated tau protein in the form of intraneuronal neurofibrillary tangles (NFT). Several risk factors have been discovered that are associated with AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Boutajangout, A., & Wisniewski, T. (2013). The innate immune system in Alzheimer's disease. International journal of cell biology. https://doi.org/10.1155/2013/576383
Vancouver
Boutajangout A, Wisniewski T. The innate immune system in Alzheimer's disease. International journal of cell biology. 2013. doi:10.1155/2013/576383. PMID: 24223593.
BibTeX
@article{boutajangout2013-24223593,
author = {Boutajangout, A. and Wisniewski, T.},
title = {{The innate immune system in Alzheimer's disease}},
journal = {International journal of cell biology},
year = {2013},
doi = {10.1155/2013/576383},
pmid = {24223593},
url = {https://doi.org/10.1155/2013/576383}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- It is characterized by two biochemically distinct types of protein aggregates: amyloid β (A β ) peptide in the forms of parenchymal amyloid plaques and congophilic amyloid angiopathy (CAA) and aggregated tau protein in the form of intraneuronal neurofibrillary tangles (NFT).
- Several risk factors have been discovered that are associated with AD.
- The most well-known genetic risk factor for late-onset AD is apolipoprotein E4 (ApoE4) (Potter and Wisniewski (2012), and Verghese et al.
- Recently, it has been reported by two groups independently that a rare functional variant (R47H) of TREM2 is associated with the late-onset risk of AD.
Why it matters
This review describes the innate immune system in Alzheimer's disease, including amyloid-beta and tau aggregates and risk factors such as ApoE4. It is a review and reports no treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of cell biology) |
| Journal's citation record | 0 / 4 | International Journal of Cell Biology: journal h-index 74 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 69 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.6 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 3 / 6 | Cited 5.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Thomas Wısnıewskı: h-index 93 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | New York University: institution h-index 1,612 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24223593) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1155/2013/576383
- PubMed: 24223593
- Original source →
- Free full text: International Journal of Cell Biology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also in TREM2 and immune genetics
79 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.